Docoh
Loading...
Sign up Log in

VTRS Viatris

Viatris is a global healthcare company formed in November 2020 through the combination of Mylan and the Upjohn Business whose mission is to empower people worldwide to live healthier at every stage of life. By integrating the strengths of these two businesses, including our global workforce of approximately 45,000 employees and contractors, Viatris aims to deliver increased access to affordable, quality medicines for patients worldwide regardless of geography or circumstance. Viatris brings together industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise complemented by a strong commitment to quality and unparalleled geographic footprint to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic and biosimilars. Viatris operates approximately 50 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.

Company profile

Ticker
VTRS
Exchange
NASDAQ
Employees
Incorporated
Delaware
Location
Pennsylvania
Fiscal year end
Dec 31
Sector
Finance and Insurance > Investment Advice
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie ...
Former names
Upjohn Inc
SEC CIK
0001792044
Corporate docs
IRS number
834364296

VTRS stock data

(
)

News

Pro users get this 30m faster
Stocks That Hit 52-Week Lows On Thursday
8 Apr 21
On Thursday morning, 6 companies achieved new lows for the year.
Analyzing Viatris's Unusual Options Activity
18 Mar 21
Shares of Viatris (NASDAQ:VTRS) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $15.08.
Morgan Stanley Maintains Equal-Weight on Viatris, Lowers Price Target to $16
10 Mar 21
Morgan Stanley analyst David Risinger maintains Viatris (NASDAQ:VTRS) with a Equal-Weight and lowers the price target from $18 to $16.
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021
8 Mar 21
10 Biggest Price Target Changes For Monday
8 Mar 21

Press releases

Pro users get this 30m faster
Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021
12 Apr 21
PITTSBURGH, April 12, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its first quarter 2021 financial results on Monday, May 10, before the open of the U.S. financial markets. The company also will host
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
8 Mar 21
PITTSBURGH and ST. PAUL, Minn., March 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of
Viatris Inc. to Participate in Barclays Global Healthcare Conference
4 Mar 21
PITTSBURGH, March 4, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced the company will take part in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday March 10, 2021. CEO
Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
1 Mar 21
Thinking about buying stock in Viatris, Energous Corp, Marathon Oil, Norwegian Cruise Line, or Snap?
22 Feb 21

Calendar

1 Mar 21
12 Apr 21
31 Dec 21

Financial summary

Financial statements Chart VTRS financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Viatris earnings reports.

Recent insider trades

VTRS insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Mar 21 Cornwell W Don Common Stock Buy Aquire P No No 13.8383 3,000 41.51K 3,000
2 Mar 21 der Meer Mohr Pauline van Common Stock Option exercise Aquire M No No 0 9,440 0 15,705
2 Mar 21 der Meer Mohr Pauline van RSU Common Stock Option exercise Dispose M No No 0 9,440 0 0
2 Mar 21 der Meer Mohr Pauline van RSU Common Stock Grant Aquire A No No 0 13,996 0 13,996
2 Mar 21 Cornwell W Don RSU Common Stock Grant Aquire A No No 0 13,996 0 13,996
2 Mar 21 Kilts James M RSU Common Stock Grant Aquire A No No 0 13,996 0 13,996
2 Mar 21 Neil F Dimick Common Stock Option exercise Aquire M No No 0 9,440 0 60,703
2 Mar 21 Neil F Dimick RSU Common Stock Option exercise Dispose M No No 0 9,440 0 0
2 Mar 21 Neil F Dimick RSU Common Stock Grant Aquire A No No 0 13,996 0 13,996
2 Mar 21 Brian Roman Common Stock Payment of exercise Dispose F No No 14.29 2,195 31.37K 38,676
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

VTRS institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

76.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 1140 0 NEW
Opened positions 1140 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 17.4B 0 NEW
Total shares 928.65M 0 NEW
Total puts 20.27M 0 NEW
Total calls 13.41M 0 NEW
Total put/call ratio 1.5 – –
Largest owners
 Shares Value Change
Vanguard 129.07M $2.42B NEW
BLK Blackrock 89.53M $1.68B NEW
Wellington Management 69.81M $1.31B NEW
STT State Street 52.54M $984.6M NEW
MCQEF Macquarie 38.41M $719.83M NEW
Capital World Investors 33.27M $623.43M NEW
Laurion Capital Management 23.23M $435.41M NEW
Geode Capital Management 22.77M $425.75M NEW
PZN Pzena Investment Management 17.09M $320.25M NEW
Deerfield Management 15.72M $294.67M NEW
Largest transactions
 Shares Bought/sold Change
Vanguard 129.07M +129.07M NEW
BLK Blackrock 89.53M +89.53M NEW
Wellington Management 69.81M +69.81M NEW
STT State Street 52.54M +52.54M NEW
MCQEF Macquarie 38.41M +38.41M NEW
Capital World Investors 33.27M +33.27M NEW
Laurion Capital Management 23.23M +23.23M NEW
Geode Capital Management 22.77M +22.77M NEW
PZN Pzena Investment Management 17.09M +17.09M NEW
Deerfield Management 15.72M +15.72M NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Coherus Biosciences
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
From filing 10-K 2020 FY

Financial reports

10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
11 Aug 20
10-Q
2020 Q1
Quarterly report
12 May 20
10-K
2019 FY
Annual report
7 May 20

Current reports

View all
8-K/A
Cost Associated with Exit or Disposal Activities
25 Feb 21
8-K
Results of Operations and Financial Condition
22 Feb 21
8-K/A
Financial Statements and Exhibits
29 Jan 21
8-K/A
Cost Associated with Exit or Disposal Activities
11 Dec 20
8-K
Entry into a Material Definitive Agreement
25 Nov 20
8-K/A
Entry into a Material Definitive Agreement
19 Nov 20
8-K
Entry into a Material Definitive Agreement
19 Nov 20
8-K
Regulation FD Disclosure
6 Aug 20
8-K
Entry into a Material Definitive Agreement
26 Jun 20
8-K
Entry into a Material Definitive Agreement
16 Jun 20

Registration and prospectus

View all
S-8
Registration of securities for employees
20 Nov 20
8-A12B
Registration of securities on exchange
10 Nov 20
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
16 Jun 20
10-12G
Registration of securities
12 Jun 20
425
Business combination disclosure
1 Jun 20
425
Business combination disclosure
29 May 20
RW
Registration withdrawal request
11 Mar 20
424B3
Prospectus supplement
13 Feb 20

Proxies

No filings

Other

View all
EFFECT
Notice of effectiveness
14 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
5 Feb 20
UPLOAD
Letter from SEC
2 Feb 20
CORRESP
Correspondence with SEC
16 Jan 20
UPLOAD
Letter from SEC
2 Jan 20
CORRESP
Correspondence with SEC
12 Dec 19
CORRESP
Correspondence with SEC
12 Dec 19
UPLOAD
Letter from SEC
21 Nov 19
UPLOAD
Letter from SEC
21 Nov 19

Ownership

View all
4
Viatris / Rajiv Malik ownership change
4 Mar 21
4
Viatris / ROBERT J COURY ownership change
4 Mar 21
4
Viatris / Sanjeev Narula ownership change
4 Mar 21
4
Viatris / Brian Roman ownership change
4 Mar 21
4
Viatris / RICHARD A MARK ownership change
4 Mar 21
4
Viatris / Dillon JoEllen Lyons ownership change
4 Mar 21
4
Viatris / MICHAEL GOETTLER ownership change
4 Mar 21
4
Viatris / Andrew Cuneo ownership change
4 Mar 21
4
Viatris / IAN C READ ownership change
4 Mar 21
4
Viatris / Paul Campbell ownership change
4 Mar 21

Reddit threads

View all